Mathias Rummel

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · The Lancet · 2013 · 1.5K citations

Medicine, Oncology, Pharmacology +6

Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study

Andreas Engert, Volker Diehl, Jeremy Franklin et al. · Journal of Clinical Oncology · 2009 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML

Sabine Käyser, Konstanze Döhner, Jürgen Krauter et al. · Blood · 2010 · 485 citations

Medicine, Hematology, Oncology +11

Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma

Mathias Rummel, S. Al-Batran, Soo-Z. Kim et al. · Journal of Clinical Oncology · 2005 · 440 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia

David J. Kuter, Mathias Rummel, Ralph V. Boccia et al. · New England Journal of Medicine · 2010 · 423 citations · Full text

Medicine, Hematology, Pharmacology +9